39 天前 - … CML or monitoring minimal residual disease (MRD) in CML patients on the therapy
with … -PCR method before its use for routine molecular monitoring for MRD according to the …

113 天前 - … that patients suffering from chronic myeloid leukemia who … -lasting molecular
responses upon treatment with tyrosine … -patient clonal heterogeneity of minimal residual disease …

157 天前 - … with high-risk myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) …
with positive molecular measurable residual disease), 22 received maintenance therapy with …

170 天前 - … for therapy and monitoring of the residual disease of patients … and the possibilities
of the patient’s region of residence. … treatment for achieving molecular responses to TKI …

201 天前 - … this, measurable residual disease (MRD) frequently persists after frontline treatment,
… cytokine IL10, and loss of key helper molecules such as CD40L. In contrast, successful …

201 天前 - … residual disease and the chemo-resistant nature of … -throughput screen of 11,140
chemical molecules in 3 stages. … after 6 days of treatment. Candidates were found to eliminate …

201 天前 - … of induction treatment for acute myeloid leukemia (AML). … early death rate, measurable
residual disease, drug toxicity, … Favorable cytogenetic/molecular risks group received four …

201 天前 - … residual disease (MRD) persisted in AML1-ETO subgroup. The early combined
response rate of patients with … response rate (CR+CRi) of molecular subgroups IDH1/2, NPM1, …

201 天前 - … Baseline demographic, clinical and molecular … residual disease (MRD), with MRD
negativity defined at a threshold of less than 10 -4 . Incidence of adverse effects and treatment …

208 天前 - … levels to monitor treatment response. Transcript typing is necessary to detect
minimal residual disease and to achieve molecular response by helping to provide selective …